The bare metal stents (BMS) market is a vital segment of the global cardiovascular device industry, used primarily in the treatment of coronary artery disease (CAD). Bare metal stents are tubular devices implanted in narrowed arteries to restore blood flow, offering significant benefits in terms of reducing restenosis (re-narrowing of arteries) compared to balloon angioplasty alone. Although drug-eluting stents (DES) have emerged as a more advanced option, BMS remains a cost-effective alternative for many patients, particularly in regions with less access to advanced healthcare technologies. The market has seen steady growth, driven by an aging global population, increasing prevalence of cardiovascular diseases, and rising awareness of heart disease treatment options.
Technological advancements in bare metal stent design, such as the development of stents with improved biocompatibility and enhanced flexibility, have contributed to their continued relevance in cardiovascular procedures. In addition, improvements in material science, such as the use of stainless steel and cobalt chromium, have helped reduce complications and improve the long-term success rate of BMS implantation. As healthcare expenditures rise and access to medical care improves, the demand for bare metal stents is expected to maintain its growth trajectory, particularly in emerging economies.
